BioSpace News Archive

Kaiser Permanente research finds older adults vaccinated with pneumococcal conjugate vaccine received some protection against COVID-19

Munich Re Life US is pleased to help fund two critical American Cancer Society Research Scholar Grants that focus on increasing the survival rates amongst breast cancer patients.

Scitara Corporation, a pioneer in digital transformation and IoLT and an emerging leader in delivering data connectivity to scientific laboratories, today announced version 1.0 of its Scitara Digital Lab Exchange (DLX™) SaaS cloud platform which dramatically advances the state of data connectivity and automation in scientific laboratories.

Sequana Medical NV, an innovator in the treatment of diuretic-resistant fluid overload in liver disease, malignant ascites and heart failure, will announce its full year results ended 31 December 2020 on Wednesday, 17 March 2021.

The elder care products comprise a range of products which are required for efficient elder care. Some of them are adult diapers, specific medicine, wheel chair, and back support.

Luminex Corporation (NASDAQ: LMNX) today announced that it has submitted an Emergency Use Authorization application to the U.S. Food and Drug Administration for the company’s new multi-analyte respiratory panel combining Flu A/B and respiratory syncytial virus (RSV) targets with the SARS-CoV-2 target.

GE Chairman and CEO H. Lawrence Culp, Jr. said, “Our team has built a strong foundation to drive improvements throughout GE.

Titan Medical Inc. (“Titan” or the “Company”) (TSX: TMD) (Nasdaq: TMDI), a medical device company focused on the design and development of surgical technologies for robotic single access surgery, today announced that, David McNally, President, CEO and Chairman and Monique Delorme, CFO of Titan Medical, will participate in two upcoming virtual investor conferences.

Zynerba Pharmaceuticals , Inc. (Nasdaq: ZYNE), the leader in innovative pharmaceutically-produced transdermal cannabinoid therapies for rare and near-rare neuropsychiatric disorders, today reported financial results for the fourth quarter and full year ended December 31, 2020, and provided an overview of recent operational highlights and a pipeline update.

AzurRx BioPharma, Inc. (“AzurRx” or the “Company”) (NASDAQ: AZRX), a company specializing in the development of targeted non-systemic, recombinant therapies for gastrointestinal (GI) diseases, announced today that James